All In Biotech

NDA 020487 · Glaxosmithkline

Valtrex

Valacyclovir Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Jun 23, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

141

22 Phase 3, 15 recruiting

FAERS reports

46,257

33,410 serious, 3,756 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

VALTREX is a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1−infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1−infected patients. 1.1 Adult Patients Cold Sores (Herpes Labialis) VALTREX is indicated for treatment of cold sores (herpes labialis). The efficacy of VALTREX initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes Initial Episode: VALTREX is indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes: VALTREX is indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with VALTREX when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy: VALTREX is indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-1−infected adults. The efficacy and safety of VALTREX for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-1−infected patients have not been established. Reduction of Transmission: VALTREX is indicated for the reduction of...

Mechanism: Valacyclovir is an antiviral drug active against α-herpes viruses [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VALTREX · VALACYCLOVIR HYDROCHLORIDE EQ 500MG BASE · TABLET, ORAL · Prescription · TE AB
  • VALTREX · VALACYCLOVIR HYDROCHLORIDE EQ 1GM BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Valacyclovir" as an intervention, any sponsor and status, largest first.

All 141 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,802
  • nausea2,783
  • fatigue2,678
  • off label use2,480
  • diarrhoea2,261
  • headache2,071
  • pyrexia2,056
  • pain1,833
  • dizziness1,622
  • vomiting1,562
  • pneumonia1,516
  • rash1,458

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004708
2005798
2006898
20071,057
20081,190
20091,149
20101,173
20111,241
20121,500
20131,127
20141,205
20151,893
20162,107
20171,692
20181,881
20192,199
20202,361
20212,984
20224,618
20234,268
20244,135
20253,689
20262,382

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Valtrex (Valacyclovir HCl)

2024 spending

$4.3M

Beneficiaries

1,209

4,107 claims

Per beneficiary

$3,551

$16.37 per unit

View as table
YearSpending
2020$5,304,186
2021$4,974,775
2022$4,932,787
2023$4,857,102
2024$4,293,428

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 241 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.